A phase 1 trial extension to assess immunologic efficacy and safety of prime-boost vaccination with VXM01, an oral T cell vaccine against VEGFR2, in patients with advanced pancreatic cancer.
about
A phase 1 trial extension to assess immunologic efficacy and safety of prime-boost vaccination with VXM01, an oral T cell vaccine against VEGFR2, in patients with advanced pancreatic cancer.
description
2018 nî lūn-bûn
@nan
2018年の論文
@ja
2018年学术文章
@wuu
2018年学术文章
@zh
2018年学术文章
@zh-cn
2018年学术文章
@zh-hans
2018年学术文章
@zh-my
2018年学术文章
@zh-sg
2018年學術文章
@yue
2018年學術文章
@zh-hant
name
A phase 1 trial extension to a ...... th advanced pancreatic cancer.
@en
A phase 1 trial extension to a ...... th advanced pancreatic cancer.
@nl
type
label
A phase 1 trial extension to a ...... th advanced pancreatic cancer.
@en
A phase 1 trial extension to a ...... th advanced pancreatic cancer.
@nl
prefLabel
A phase 1 trial extension to a ...... th advanced pancreatic cancer.
@en
A phase 1 trial extension to a ...... th advanced pancreatic cancer.
@nl
P2093
P2860
P50
P1433
P1476
A phase 1 trial extension to a ...... th advanced pancreatic cancer.
@en
P2093
Anne-Valerie Keller
Christoph Springfeld
Friedrich H Schmitz-Winnenthal
Heinz Lubenau
Klaus M Breiner
Lars Grenacher
Lilli Podola
Marco Springer
Mariana Bucur
Nicolas Hohmann
P2860
P304
P356
10.1080/2162402X.2017.1303584
P577
2018-01-16T00:00:00Z